verified COP 10,1 · D1 • database Scopus / SJR & Web of Science indexed

United Kingdom · Elsevier Ltd

workspace_premium D1 Top 10% — Oncology visibility_off Single blind Peer Review lock_open Open Access

The Lancet Oncology

The Lancet Oncology is a journal indexed in SJR in Oncology with an H index of 432. Journal with a Single blind Peer Review review system, and It has a price of 2395 €. The scope of the journal is focused on Oncology, Cancer,. It has a COP Index of 10,1 (best band D1). It is published in English. It has a COP Index of 10,1.

The Lancet Oncology focuses its scope in these topics and keywords: cancer, phase, patients, randomised, metastatic, care, advanced, openlabel, multicentre, doubleblind, ...

ISSN: 1470-2045

Publisher: Elsevier Ltd

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Visit publisher site menu_book Author guidelines

schedule CountryOfPapers database fields

COP Index trending_up

10,1 D1 Top 10%

16 of 322 journals in Oncology

H-index · SJR 432 · 11,319

Acceptance rate pie_chart

16% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

COP Index

10,1

D1 Top 10%

SJR Impact

11,319

H-index

432

Docs (year)

475

Docs 3y

1353

Total refs

7356

Cites 3y

15163

Citable 3y

636

Cites/Doc 2y

9.61

Ref/Doc

15.49

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Australian scientists design novel antiangiogenic weapon

Why do hypoxic cells behave badly?

Chlorophyllin reduces risk of aflatoxin-induced liver cancer

Chemotherapy and anaesthetic drugs: too little is known

Chemoprevention: eat ginger, rub on pomegranate

CCI-779: a new targeted anticancer agent

Cancer sites for children are few and far between

Cancer Institute at Chennai: a model for resource-poor countries

Cancer and ethnic minorities

Canadian researchers uncover vital new clues in cancer

Bring back the acetyls - a novel anticancer movement

Breast reconstruction cannot exorcise phantom pain

SHOW MORE ARTICLES

Breast cancer in women after treatment for Hodgkin's disease

A new approach to managing prostate cancer is essential

Australian cancer survival figures greatly improved

Australia approves thalidomide

Association of the British Pharmaceutical Industry says...

An extra defence against skin cancer?

Amgen's point of view on epoetins

Alternative medicine and cancer patients in less developed countries

Alternative cancer cures

Allan van Oosterom, President of the EORTC

Alan Coates -CEO of the Australian Cancer Society

Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28

FAQs

The Lancet Oncology has a COP Index of 10,1 (D1), ranked 16 of 322 in Oncology. SJR: 11,319.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for The Lancet Oncology is 16%.

The Lancet Oncology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the COP Index of The Lancet Oncology?

What is the APC / publication cost?

What is the acceptance rate?